|
|
Article: Kibow Biotech Enters US Consumer Dietary Supplement Market with Kibow Flora(TM) and Three Related Products Targeting the Risk Factors of Metabolic Syndrome.
- Article from:
- PR Newswire
- Article date:
- November 14, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA, Nov. 14 /PRNewswire/ -- Kibow Biotech, Inc. marked its first decade of activity by announcing today the launch of Kibow Flora(TM), the first probiotic and prebiotic combination specifically developed for Metabolic Syndrome. Metabolic Syndrome (also referred to as Syndrome-X), is a disorder affecting an estimated 22% of US adults and 4.2% of US adolescents.
In addition to Kibow Flora(TM), the Company's new Metabolic Syndrome range includes three related products -- Kibow C-12 peptide, Kibow Acetyl-L- Carnitine and Kibow L-Theanine. According to the indication, each product may be taken separately or together with Kibow Flora. All ingredients in ...